3-{(5-oxo-1-(3-{((N-propylcarbamoyl)methyl)amino}phenyl)pyrrolidin-3-yl)carbonylamino}-3-(3-pyridyl)propanoic acid | 345296-22-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: 3-{(5-oxo-1-(3-{((N-propylcarbamoyl)methyl)amino}phenyl)pyrrolidin-3-yl)carbonylamino}-3-(3-pyridyl)propanoic acid
• 英文别名: 3-{(5-oxo-1-(3-{((N-propylcarbamoyl)methyl)amino}phenyl)pyrrolidin-3-yl)carbonylamino}-3-(pyridin-3-yl)propanoic acid；3-[[5-Oxo-1-[3-[[2-oxo-2-(propylamino)ethyl]amino]phenyl]pyrrolidine-3-carbonyl]amino]-3-pyridin-3-ylpropanoic acid
• CAS: 345296-22-2
• 化学式: C₂₄H₂₉N₅O₅
• 分子量: 467.525
• InChiKey: YOSPAMZVGIGBCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  141
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Integrin inhibitors and their methods of use
  申请人：——

  公开号：US20020019402A1

  公开（公告）日：2002-02-14

  The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as a &agr; v &bgr; 3 , &agr; v &bgr; 6 , &agr; 5 &bgr; 1 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  该发明涉及新型化合物，对预防和治疗疾病（如整合素受体介导的疾病，特别是由整合素受体介导的疾病或病况，如αvβ3、αvβ6、α5β1等）具有有效性。该发明涵盖了新型化合物、其药用可接受盐、药物组合物以及预防和治疗此类疾病和疾患的方法。该发明还涉及制备此类化合物的工艺以及在此类工艺中有用的中间体。
• US6849639B2
  申请人：——

  公开号：US6849639B2

  公开（公告）日：2005-02-01